Irinotecan and platinums in the treatment of non-small-cell lung cancer

Clinical Lung Cancer

Volumn 2, Issue SUPPL. 2, 2001, Pages

  Bunn P A , Jr ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Chemotherapy; Cisplatin; Irinotecan; Lung cancer

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN; VINDESINE;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEATH; DIARRHEA; DRUG ACTIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK; SEX RATIO; STANDARD; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TIME; UNITED STATES; VOMITING;

EID: 0034952166     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/clc.2001.s.003     Document Type: Article

References (48)

1. Cancer statistics, 2000
2. Classification, histology, cytology and electron microscopy
3. Diagnosis of lung cancer: Pathology of invasive and preinvasive neoplasia
4. Non-small cell lung cancer
5. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
6. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
7. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
8. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
9. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
10. Phase III comparison of sequential vs concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410
11. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer
12. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer
13. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
14. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
15. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
16. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Group trial
17. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
18. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
19. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
20. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
21. Paclitaxel and carboplatin in inoperable non-small cell lung cancer: A phase II study
22. DNA topoisomerase I poisons
23. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
24. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer
25. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC)
26. An early phase II study of CPT-11 in primary lung cancer
27. Phase II study of CPT-11 (irinotecan) in non small cell lung cancer (NSCLC)
28. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
29. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
30. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
31. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
32. A phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small cell lung cancer
33. Phase II study irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer
34. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
35. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer
36. Phase II multi-institutional study of irinotecan (CPT-11) and cisplatin (CDDP) on a three-week schedule in patients with advanced non-small cell lung cancer (NSCLC)
37. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter phase II study
38. Fractionated administration of cisplatin (CDDP) and irinotecan (CPT-11) in patients with stage IIIB and IV non-small-cell lung cancer (NSCLC): A phase II study
39. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
40. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer
41. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers
42. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
43. Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC)
44. Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small-cell lung cancer (NSCLC); a West Japan Thoracic Oncology Group (WJTOG) study
45. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer
46. A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer
47. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin
48. A dose-escalation study of irinotecan (CPT-II) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy